The Effectiveness of Risankizumab as Induction Therapy for Crohn’s Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases

This multicentre cohort study showed that Risankizumab is an effective induction therapy in patients with Crohn’s disease, and that the best results are obtained when Risankizumab is used as second-line therapy following a previous failure with a TNF inhibitor.